STOCK TITAN

Repare Therapeutics Inc. Common Shares - $RPTX STOCK NEWS

Welcome to our dedicated page for Repare Therapeutics Common Shares news (Ticker: $RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics Common Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Repare Therapeutics Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Repare Therapeutics Common Shares's position in the market.

Rhea-AI Summary
Repare Therapeutics Inc. (Nasdaq: RPTX) announces the development of RP-1664, a potent PLK4 inhibitor, and RP-3467, a Polθ inhibitor, with promising preclinical data. RP-1664 shows synthetic lethality in TRIM37-high tumors, while RP-3467 demonstrates complete regressions in combination with PARPi and anti-tumor activity with RLT and chemotherapy. Clinical trials for RP-1664 and RP-3467 are expected to start in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.66%
Tags
-
Rhea-AI Summary
Repare Therapeutics Inc. (RPTX) reported positive initial data from the ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily pre-treated gynecological tumors. They also announced a conference call and webcast to discuss the latest data from their preclinical programs and overall pipeline on November 15th, 2023 at 8:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
-
Rhea-AI Summary
VedaBio, a biotechnology company, announced the formation of its scientific advisory board with world-class experts. They have unveiled the CRISPR Cascade™, a platform that delivers near-instant detection of analytes with best-in-class accuracy, backed by an initial funding of over $40 Million. The SAB members include Dr. Rashid Bashir, Dr. Daniel Durocher, Dr. Patrick Hsu, and Dr. David Perlin, who bring extensive expertise to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
management
Rhea-AI Summary
Repare Therapeutics Inc. will host a live webcast to present the latest data from its ongoing preclinical programs, RP-1664 and RP-3467, on November 15 at 8:00 a.m. ET. The webcast will be available on the Investor section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
conferences
-
Rhea-AI Summary
Repare Therapeutics Inc. announced that its senior management team will participate in two investor conferences in November. The first conference is the Stifel 2023 Healthcare Conference on November 14th at 8:35 a.m. Eastern Time in New York, NY. The second conference is the Piper Sandler 35th Annual Healthcare Conference on November 28th at 10:30 a.m. Eastern Time, also in New York, NY. The fireside chats will be webcasted live on the company's website, with a replay available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.7%
Tags
conferences
-
Rhea-AI Summary
Repare Therapeutics reports positive initial data from Phase 1 MYTHIC clinical trial evaluating lunresertib and camonsertib combination for treating solid tumors. Encouraging safety and tolerability profile observed. Overall response of 33.3% across all tumor types and 50% RECIST response in heavily pre-treated gynecologic tumors. Lunresertib shows potential as a clinical-stage PKMYT1 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.58%
Tags
conferences clinical trial
-
Rhea-AI Summary
Repare Therapeutics to present initial data from Phase 1 MYTHIC clinical trial at AACR-NCI-EORTC conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.23%
Tags
conferences clinical trial
-
Rhea-AI Summary
Repare Therapeutics to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
conferences
Rhea-AI Summary
Repare Therapeutics reports progress in clinical programs, including positive data for camonsertib-PARPi combination and lunresertib monotherapy. FDA grants Fast Track designation to lunresertib in combination with camonsertib for endometrial cancer. Cash and cash equivalents at $280.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.1%
Tags
Repare Therapeutics Inc. Common Shares

Nasdaq:RPTX

RPTX Rankings

RPTX Stock Data

146.44M
14.92M
1.02%
94.48%
1.61%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAINT-LAURENT

About RPTX

repare therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. its approach integrates insights from several fields of cell biology including dna repair and synthetic lethality. repare’s platform combines a proprietary, high throughput, crispr‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics. the company is backed by leading global healthcare investors including founding investor versant ventures and mpm capital. for additional information, please visit www.reparerx.com.